drugset / Trial / NCT04976218
TGFβR-KO CAR-EGFR T Cells in Previously Treated Advanced EGFR-positive Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
Chimeric antigen receptor modified T (CART) cell therapy has been identified as a breakthrough therapy in hematologic malignancies. However, CART cell therapy yielded no satisfactory efficacy data in the study of solid tumors. One of major challenges is the complicated immunosuppressive tumor microenvironment (TME) in solid tumors. It has been reported that transforming growth factor-β (TGF-β) is one of the major regulatory factors in the TME. In this study, we construct CAR-EGFR-TGFβR-KO T cell by knocking out TGF-β receptor Ⅱ through CRISPR/Cas9 in order to study the anti-tumor activities and safety profiles of CAR-EGFR-TGFβR-KO T cell in previously treated advanced EGFR positive solid tumors.
Timeline
- Start
- 2022-03-15
- Primary completion
- 2023-12-20
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TGFβR-KO CAR-EGFR T Cells | Unknown | 100000 cells/kg | — |
| Subject | TGFβR-KO CAR-EGFR T Cells | Unknown | 200000 cells/kg | — |
| Subject | TGFβR-KO CAR-EGFR T Cells | Unknown | 1e+06 cells/kg | — |
| Subject | TGFβR-KO CAR-EGFR T Cells | Unknown | 5e+06 cells/kg | — |
| Subject | TGFβR-KO CAR-EGFR T Cells | Unknown | 1e+07 cells/kg | — |